722 related articles for article (PubMed ID: 31569068)
1. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
[TBL] [Abstract][Full Text] [Related]
2. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
4. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
6. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
7. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
8. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
9. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
[TBL] [Abstract][Full Text] [Related]
10. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
12. EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
Cardona AF; Ordóñez-Reyes C; Ruiz-Patiño A; Garcia-Robledo JE; Barron LZ; Recondo G; Rojas L; Corrales L; Martín C; Barrón F; Sotelo C; Rodríguez J; Ricaurte L; Rolfo C; Ávila J; Mayorga D; Archila P; Otero J; Mas L; Bermudez M; Gamez T; Carranza H; Vargas C; Rosell R; Arrieta O
JCO Precis Oncol; 2021 Nov; 5():839-848. PubMed ID: 34994616
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
[TBL] [Abstract][Full Text] [Related]
14. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W
Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study.
Hou X; Li M; Wu G; Feng W; Su J; Jiang H; Jiang G; Chen J; Zhang B; You Z; Liu Q; Chen L
JAMA Netw Open; 2023 Feb; 6(2):e2255050. PubMed ID: 36753281
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study.
Yu Y; Wang Y; Wu L; Xu X; Zhou H; Wang Q; Zhou J
Medicine (Baltimore); 2021 Feb; 100(5):e23712. PubMed ID: 33592829
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]